60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) has announced that it has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree, for non-prescription uses.
The company reports that according to recent scientific literature, at low doses, castanospermine modulates carbohydrate metabolism, altering glycogen, glucose levels and other clinical markers. In animal models, high doses have been shown to impact disease outcomes in several therapeutic areas through immunomodulation.
The FDA has issued a Non-Notification Letter to 60 Degrees providing feedback on its recent filing of a New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract. The company and the FDA will meet on July 1, 2026, to discuss the feedback, including clarification regarding the minimum required other safety information to establish the safety of the proposed use of Australian Chestnut Extract in a dietary supplement.
